The device called a HairMax Laser Comb is already on the market. But the Food and Drug Administration is now allowing it to be sold as a treatment for the most common form of male baldness, based on studies conducted by the company

Dr. Marc Avram is a Cosmetic Dermatologist who has some familiarity with the product, "It is a new therapy that is not a magical cure unfortunately. But for some patients it will be helpful to help maintain or re-grow some hair."

According to the directions on the product, a person is supposed to comb his hair with the device three times a week. The laser light causes thinning hair follicles to expand in some people.

Experts say the device is not as effective as Rogaine or Propecia, the two medications approved to treat hair loss.

HairMax Lasercomb Cleared by FDA for Hair Loss Treatment

Lexington International LLC is proud to announce the landmark achievement of US Food & Drug Administration (FDA) clearance for their medical laser device, the HairMax LaserComb®. Through years of extensive research and clinical studies in the science of hair growth, Lexington has developed an affordable and convenient, hand-held laser device, now clinically proven to promote hair growth in males with androgenetic alopecia (Norwood IIA to V with Fitzpatrick skin types I to IV). 

This FDA clearance of the HairMax LaserComb offers an exciting new modality for the promotion of hair growth in males.  Until now, the FDA has only approved two other products as solutions to combat hair loss, a condition that affects approximately 55 million men in the U.S.  But the HairMax LaserComb stands out as the only proven drug-free alternative.  This gives many hair loss sufferers, previously unable or unwilling to turn to drug-based solutions, newfound hope in their battle.

Palomar Medical Reports Fourth Quarter 2006 Financial Results

BURLINGTON, Mass., Feb. 8 /PRNewswire-FirstCall/ -- Palomar Medical Technologies, Inc. (NASDAQ:PMTI) , a leading researcher and developer of light-based systems for cosmetic treatments, today announced financial results for the fourth quarter and year ended December 31, 2006. Revenues for the quarter ended December 31, 2006 were $39.4 million, which represents an 82 percent increase over the $21.6 million reported in the fourth quarter of 2005. The increase in revenues for the quarter ended December 31, 2006 compared to 2005 includes back-owed royalty revenues of $10.6 million comprised of $10.0 million from the execution of a patent license agreement with Cynosure, Inc. in the fourth quarter of 2006 and $595,000 in additional back-owed royalties resulting from the completion of a royalty audit of Cutera, Inc.'s settlement payment.